Literature DB >> 10191209

Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB.

J F Carlquist1, L Edelman, D W Bennion, J L Anderson.   

Abstract

Cytomegalovirus (CMV) infection induces the proinflammatory cytokine, interleukin (IL)-6, which may contribute to the pathology of the infection. In vitro CMV induction of IL-6 by human lung fibroblasts was studied. The quantity of cytokine in culture supernatants was maximal 20 h after infection and decreased thereafter. Transcription of the IL-6 gene and IL-6 protein expression were equally stimulated by infectious and UV-inactivated virus (CMV-UV). CMV-UV-stimulated IL-6 was inhibited by pyrrolidinedithiocarbamate (an inhibitor of the transcription factor, NF-kappaB) and by pertussis toxin (suggesting the involvement of a G protein) and occurred in the absence of CMV immediate-early antigen transcription. Neutralizing antibodies to IL-1beta or tumor necrosis factor-alpha did not affect CMV-UV-induced IL-6, but expression was inhibited by antibody to the CMV attachment glycoprotein. IL-6 production by fibroblasts occurs independently from productive infection but has characteristics that suggest a ligand receptor-mediated pathway. This function may be important in pathology or disease resolution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10191209     DOI: 10.1086/314734

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Modulation of the NFκb Signalling Pathway by Human Cytomegalovirus.

Authors:  Meaghan H Hancock; Jay A Nelson
Journal:  Virology (Hyderabad)       Date:  2017-07-31

3.  Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Martin Zydek; Lenore Pereira
Journal:  Am J Pathol       Date:  2016-09-13       Impact factor: 4.307

Review 4.  Current Understanding of Cytomegalovirus Reactivation in Critical Illness.

Authors:  Hannah Imlay; Ajit P Limaye
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

5.  Posttranscriptional suppression of interleukin-6 production by human cytomegalovirus.

Authors:  Claire Gealy; Marian Denson; Christine Humphreys; Brian McSharry; Gavin Wilkinson; Richard Caswell
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes.

Authors:  S R Paludan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals.

Authors:  Sara Gianella; Antoine Chaillon; Ece A Mutlu; Phillip A Engen; Robin M Voigt; Ali Keshavarzian; John Losurdo; Prachi Chakradeo; Steven M Lada; Masato Nakazawa; Alan L Landay
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

8.  Murine cytomegalovirus (CMV) M33 and human CMV US28 receptors exhibit similar constitutive signaling activities.

Authors:  Maria Waldhoer; Thomas N Kledal; Helen Farrell; Thue W Schwartz
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality.

Authors:  W L William Chang; Nicole Baumgarth; Dong Yu; Peter A Barry
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Serum levels of interleukin 6 in recently hospitalized tick-borne encephalitis patients correlate with age, but not with disease outcome.

Authors:  M G Toporkova; S E Aleshin; S V Ozherelkov; M V Nadezhdina; J R Stephenson; A V Timofeev
Journal:  Clin Exp Immunol       Date:  2008-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.